Immunomodulatory effects of intravenous immunoglobulins (IVIg) in autoimmune diseases abstract;Effets immunomodulateurs des immunoglobulines intraveineuses au cours des maladies auto-immunes

Revue de Medecine Interne

Volumn 20, Issue SUPPL. 4, 1999, Pages 423-430

  Mouthon, L ^a,b   Lacroix Desmazes, S ^a   Pashov, A ^a   Kaveri, S V ^a   Kazatchkine, M D ^a  

^a HÔPITAL BROUSSAIS   (France)

^b AVICENNE HOSPITAL   (France)

Author keywords

Apoptosis; Autoimmunity; Intravenous immunoglobulin; V region

Indexed keywords

AUTOANTIBODY; CYTOKINE; FC RECEPTOR; IMMUNOGLOBULIN;

APOPTOSIS; AUTOIMMUNE DISEASE; DRUG EFFECT; HUMAN; IMMUNOLOGY; LYMPHOCYTE; MONOCYTE; REVIEW; TREATMENT OUTCOME;

APOPTOSIS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CYTOKINES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LYMPHOCYTES; MONOCYTES; RECEPTORS, FC; TREATMENT OUTCOME;

EID: 0032605977     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Dalakas MC. Intravenous immune globulin therapy for neurologic diseases. Ann Int Med 1997; 126 : 721-30.
2. Dwyer JM. Manipulating the immune system with immune globulin. New Engl J Med 1992; 326 : 107-16.
3. Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gammaglobulin. New Engl J Med 1982; 306 : 1254-8.
4. Kimberly RP, Salmon JE, Bussel JB, Kuntz-Crow M, Hilgartner MW. Modulation of mononuclear phagocyte function by intravenous gamma globulin. J Immunol 1984; 132 : 745-50.
5. Clarkson SB, Bussel JB, Kimberly RP, Valinsky JE, Nachman RL, Unkeless JC. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. New Engl J Med 1986; 314 : 1236-9.
6. Salama A, Mueller-Eckhardt C, Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia. Competitive inhibition of reticuloendothelial system function by sequestration of autologous red blood cells? Lancet 1983; ii : 193-5.
7. Debré M, Bonnet MC, Fridman WH, Carosella E, Philippe N, Reinert P, et al. Infusion of Fcg fragments for the treatment of children with acute immune thrombocytopenic purpura. Lancet 1993; 342 : 945-9.
8. Berchtold P, Dale GL, Tani P, McMillan R. Inhibition of autoantibody binding to platelet glycoprotein IIb/IIIa by antiidiotypic antibodies in intravenous immunoglobulins. Blood 1989; 74 : 2414-7.
9. Basta M, Kirshbom P, Frank MM, Fries LF. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest 1989; 84 : 1974-81.
10. Lin RY, Racis SP. In vivo reduction of circulating C1q binding immune complexes by intravenous gammaglobulin administration. Int Arch Allergy Appl Immunol 1986; 79 : 286-90.
11. Basta M, Langlois PF, Marques M, Frank MM, Fries LF. High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. Blood 1989; 74 : 326-33.
12. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complements fragments. J Clin Inv 1994; 94 : 1729-35.
13. Andersson UG, Bjork L, Skansén-Saphir U, Andersson JP. Down-regulation of cytokine production and IL-2 receptor expression by pooled human IgG. Immunology 1993; 79 : 211-6.
14. Amran A, Renz H, Lack G, Bradley K, Gelfand EW. Suppression of cytokine-dependant human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 1994; 73 : 180-6.
15. Ling ZD, Yeoh E, Webb BT, Farrell K, Doucette J, Matheson DS. Intravenous immunoglobulin induces interferon-g and interleukin-6 in vivo. J Clin Immunol 1993; 13 : 302-9.
16. Ruiz-de-Souza V, Carreno MP, Kaveri SV, Cavaillon JM, Kazatchkine MD, Haeffner-Cavaillon N. Selective induction of IL-1ra and IL-8 in human monocytes by normal polyspecific immunoglobulin G for therapeutic use (IVIg). Eur J Immunol 1995; 25 : 1267-73.
17. Arend WP, Smith MF, Janson RW, Joslin FG. IL-1 receptor antagonist and IL-1β production in human monocytes are regulated differently. J Immunol 1991; 147 : 1530-6.
18. Leung D, Kurt-Jones E, Newburger J, Cotran R, Burns J, Prober J. Endothelial cell activation of high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet 1989; ii : 1298-302.
19. Poutsiaka DD, Clark BD, Vannier E, Dinarello CA. Production of IL-1 receptor antagonist and IL-1β by peripheral blood mononuclear cells is differentially regulated. Blood 1991; 78 : 1275-9.
20. Shimozato T, Iwata M, Kawada H, Tamura N. Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3': 5'-monophosphate levels, resulting in suppression of tumor necrosis factor alpha and interleukin-1 production. Immunology 1991; 72 : 497-501.
21. Aukrust P, Froland SS, Liabakk NB, Muller F, Nordoy I, Haug C, et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994; 84 : 2136-43.
22. Rowley AH, Gonzalez-Crussi F, Shulman ST. Kawasaki Syndrome. Curr Prob Pediat 1991; 21 : 387-405.
23. Saoudi A, Hurez V, de Kozak Y, Kuhn J, Kaveri SV, Kazatchkine MD, et al. Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis. Int Immunol 1993; 5 : 1559-67.
24. Pashov A, Dubey C, Kaveri SV, Lectard B, Huang YM, Kazatchkine MD, et al. Normal immunoglobulin G protects against experimental allergic encephalomyelitis by inducing transferable T cell unresponsiveness to myelin basic protein. Eur J Immunol 1998; 28 : 1823-31.
25. Rossi F, Sultan Y, Kazatchkine MD. Anti-idiotypes against autoantibodies and alloantibodies to Factor VIII: C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Clin Exp Immunol 1988; 74 : 311-6.
26. Rossi F, Dietrich G, Kazatchkine MD. Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulation of human autoimmune responses. Immunol Rev 1989; 110 : 135-49.
27. van Doom PA, Rossi F, Brand A, van Lint M, Vermeulen M, Kazatchkine MD. On the mechanism of high dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 1990; 29 : 57-64.
28. Rossi F, Jayne DRW, Lockwood CM, Kazatchkine MD. Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol 1991; 83 : 298-303.
29. Ronda N, Haury M, Nobrega A, Coutinho A, Kazatchkine MD. Selectivity of recognition of variable (V) regions of autoantibodies by intravenous immunoglobulin (IVIg). Clin Immunol Immunopathol 1994; 70 : 124-8.
30. Dietrich G, Pereira P, Algiman M, Sultan Y, Kazatchkine MD. A monoclonal anti-idiotypic antibody against the antigen-combining site of anti-factor VIII autoantibodies defines an idiotope that is recognized by normal human polyspecific immunoglobulins for therapeutic use (IVIg). J Autoimmun 1990; 3 : 547-57.
31. Dietrich G, Kazatchkine MD. Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest 1990; 85 : 620-5.
32. Kaveri SV, Wang HT, Rowen D, Kazatchkine MD, Kohler H. Monoclonal anti-idiotypic antibodies against human anti-thyroglobulin autoantibodies recognize idiotopes shared by disease-associated and natural anti-thyroglobulin autoantibodies. Clin Immunol Immunopathol 1993; 69 : 333-40.
33. Dwyer DS, Bradley RJ, Urquhart CK, Kearney JF. Naturally occurring anti-idiotypic antibodies in myasthenia gravis patients. Nature 1983; 301 : 611-4.
34. Zouali M, Eyquem A. Idiotypic/antiidiotypic interactions in systemic lupus erythematosus: demonstration of oscillary levels of anti-DNA autoantibodies and reciprocal antiidiotypic activity in a single patient. Ann Inst Pasteur Immunol 1983; 134C : 377-91.
35. Sultan Y, Rossi F, Kazatchkine MD. Recovery from anti-VIII: C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII: C autoantibodies. Proc Natl Acad Sci 1987; 84 : 828-31.
36. Dietrich G, Algiman M, Sultan Y, Nydegger UE, Kazatchkine MD. Origin of anti-idiotypic activity against anti-factor VIII autoantibodies in pools of normal human immunoglobulin G (IVIg). Blood 1992; 79 : 2946-51.
37. Roux KH, Tankersley DL. A view of the human idiotypic repertoire: electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG. J Immunol 1990; 144 : 1387-95.
38. Dietrich G, Kaveri SV, Kazatchkine MD. A V region-connected autoreactive subfraction of normal human serum immunoglobulin G. Eur J Immunol 1992; 22 : 1701-6.
39. Vassilev T, Gelin C, Kaveri SV, Zilber MT, Boumsell L, Kazatchkine MD. Antibodies to the CDS molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol 1993; 92 : 369-72.
40. Dietrich G, Varela F, Hurez V, Bouanani M, Kazatchkine MD. Selection of the expressed B cell repertoire by infusion of normal immunoglobulin G in a patient with autoimmune thyroiditis. Eur J Immunol 1993; 23 : 2945-50.
41. Prasad NKA, Papoff G, Zeuner A, Bonnin E, Kazatchkine MD, Ruberti G, et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 1998; 161 : 3781-90.
42. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. Inhibition of toxic epidermal necrosis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282 : 490-3.
43. Marchalonis JJ, Kaymaz H, Dedeoglu F, Schlutter SF, Yocum DE, Edmundson AB. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor β chain. Proc Natl Acad Sci 1992; 89 : 3325-9.
44. Hurez V, Kaveri SV, Mouhoub A, Dietrich G, Mani JC, Klatzmann D, et al. Anti-CD4 activity of normal human immunoglobulins G for therapeutic use (intravenous immunoglobulin, IVIg). Therap Immunol 1994; 1 : 269-78.
45. Clayberger C, Lyu SC, Pouletty P, Krensky AM. Peptides corresponding to T-cell receptor-HLA contact regions inhibit class I-restricted immune responses. Transpl Proc 1993; 25 : 477-8.
46. Kaveri SV, Vassilev T, Hurez V, Lengagne R, Lefranc C, Cot S, et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CDS T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 1996; 97 : 865-9.